Thus, the co-delivery of TRAIL and NO by a stroma-targeted nanogel that remodels the fibrotic tumor microenvironment and suppresses tumor growth is promising for PDAC treatment [89]. The gene discussed is TNFSF10; the disease is neoplasm.